Literature DB >> 29054784

Developing a xenograft human tumor model in immunocompetent mice.

Matthew T Basel1, Sanjeev Narayanan2, Chanran Ganta3, Tej B Shreshta4, Alejandro Marquez5, Marla Pyle6, Jennifer Hill7, Stefan H Bossmann8, Deryl L Troyer9.   

Abstract

Animal models are essential to cancer research, but current xenograft models are limited in their utility especially due to the lack of an immune system. Here we demonstrate that a xenograft tumor model can be developed in immunocompetent mice by tolerizing murine fetuses to human tumor cells. A375 human melanoma cells were injected into day E14 fetuses and after birth mice were challenged with A375 cells to determine their ability to develop tumors. Intravenous injections of cells resulted in metastatic-like lung tumors, which were verified to be human in origin by immunohistochemistry and PCR. These results were replicated with several other human tumor types: BxPC3 (human pancreatic adenocarcinoma), MDA-MB-231 (human breast adenocarcinoma), M21 (human melanoma), and HeLa (human cervical adenocarcinoma). Development of an immunocompetent xenograft tumor model would allow the further elucidation of the interaction of the immune system with therapy in both preclinical research and patient derived xenografts.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fetal surgery; Immunocompetent; Model; Tolerization; Xenograft

Mesh:

Year:  2017        PMID: 29054784     DOI: 10.1016/j.canlet.2017.10.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Relevance of humanized three-dimensional tumor tissue models: a descriptive systematic literature review.

Authors:  D Contartese; Francesca Salamanna; F Veronesi; M Fini
Journal:  Cell Mol Life Sci       Date:  2020-04-13       Impact factor: 9.261

2.  Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models.

Authors:  Ming Yuan; David White; Linda Resar; Eli Bar; Mari Groves; Alan Cohen; Eric Jackson; Jennifer Bynum; Jeffrey Rubens; Jeff Mumm; Liam Chen; Liqun Jiang; Eric Raabe; Fausto J Rodriguez; Charles G Eberhart
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 13.029

Review 3.  Patient-derived xenograft models in musculoskeletal malignancies.

Authors:  Wan Lu; Tu Chao; Chen Ruiqi; Su Juan; Li Zhihong
Journal:  J Transl Med       Date:  2018-04-23       Impact factor: 5.531

4.  Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.

Authors:  Lanxiang Huang; Yuan Rong; Xuan Tang; Kezhen Yi; Peng Qi; Jinxuan Hou; Weihuang Liu; Yuan He; Xing Gao; Chunhui Yuan; Fubing Wang
Journal:  Mol Cancer       Date:  2022-02-11       Impact factor: 27.401

5.  Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD-1 antagonist in CD4-depleted mice.

Authors:  Soon-Hyun Ahn; Joo Yeon Choi; Seong Dong Kim; Sung Joon Park; Hyojin Kim
Journal:  Oncol Lett       Date:  2019-10-14       Impact factor: 2.967

6.  Establishment of a Human Gastric Cancer Xenograft Model in Immunocompetent Mice Using the Microcarrier-6.

Authors:  Yanzhen Bi; Quanyi Wang; Yonghong Yang; Quanquan Wang; Kai Zhang; Xiaobei Zhang; William C Cho; Zhenfeng Shu; Jiannan Li; Lili Liu; Chuanping Si; Feng Hong
Journal:  Biomed Res Int       Date:  2020-04-04       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.